TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28556432

Group type: EXPERIMENTAL
Intervention: One-piece dental implants (S1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two-piece dental implants (S2)
Number of subjects: 60
Study: 25981812

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lobectomy with mediastinal lymph node dissection or sampling (surgery)
Number of subjects: 58
Study: 23649498

Group type: EXPERIMENTAL
Intervention: Montgomery Safe‐T‐Tube removed 3 to 15 days after insertion (group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Montgomery Safe‐T‐Tube removed at least 90 days after insertion (group B)
Number of subjects: 16
Study: 21411512

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant methionyl human leptin (30 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose recombinant methionyl human leptin (80 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 18923838

Group type: EXPERIMENTAL
Intervention: Rheopheresis (two treatments, each lasting about 2 hours, within 3 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (i.v. corticosteroids: methylprednisolon 250 mg for 3 days and tapering to zero, or i.v. hemodilution: 500 mL 6% hydroxyethyl starch plus 600 mg pentoxifylline per day for 10 days)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rheopheresis
Number of subjects: 240
Study: 16583215

Group type: EXPERIMENTAL
Intervention: Gd-DTPA contrast agent during bolus administration
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: T2* measurements
Number of subjects: 28
Study: 14747688

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 2970

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 2970
Study: 11232003

Group type: EXPERIMENTAL
Intervention: Low fat meal (LF; 20% fat, 68% carbohydrate, 12% protein)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High fat meal (HF; 48% fat, 40% carbohydrate, 12% protein)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low fat meal (LF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High fat meal (HF)
Number of subjects: 11
Study: 9262538

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 240
Study: 8517102

Group type: EXPERIMENTAL
Intervention: Isoflurane (3.75 vol‐% in 70% nitrous oxide in oxygen)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 36
Study: 3629090

Group type: EXPERIMENTAL
Intervention: 0.5 mg arecoline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.2 mg glycopyrrolate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study: 29324401

Group type: COMPARATOR
Intervention: Controlled-release carbamazepine monotherapy (CBZ-CR)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Lamotrigine and valproate combination therapy (LTG+VPA)
Number of subjects: 207
Study: 26924671

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise and muscle-strengthening exercises, 20 weeks, 3-5 sessions per week of 90 minutes each.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 100
Study: 24511907

Group type: EXPERIMENTAL
Intervention: Computer-mediated social support (CMSS) groups
Number of subjects: 111
Study: 21254378

Group type: EXPERIMENTAL
Intervention: Initial lumbar puncture on day 8 in remission induction therapy
Number of subjects: 754

Group type: COMPARATOR
Intervention: Initial lumbar puncture on day 1 (previous studies)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Overall event-free survival at 4 years
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Four-year cumulative incidence of any CNS relapse
Number of subjects: 754
Study: 20354750

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenous monthly for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18048433

Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg/day for 1 week)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16523204

Group type: EXPERIMENTAL
Intervention: Sugar beet pectin (SBP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no fiber enrichment)
Number of subjects: 66
Study: 14586912

Group type: EXPERIMENTAL
Intervention: BWS group (body-weight support)
Number of subjects: 100

Group type: COMPARATOR
Intervention: no-BWS group (full weight bearing)
Number of subjects: 100
Study: 10764307

Group type: EXPERIMENTAL
Intervention: PPD-S1
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: PPD-S2
Number of subjects: 1258
Study: 8923024

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (beta-carotene, vitamin C, and vitamin E) for three years
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Placebo for three years
Number of subjects: 2200
Study: 1356479

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 15
Study: 31486188

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11096
Study: 29778606

Group type: EXPERIMENTAL
Intervention: Avatrombopag 60 mg
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Avatrombopag 40 mg
Number of subjects: 435

Group type: COMPARATOR
Intervention: Avatrombopag
Number of subjects: 435
Study: 27922020

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg every other day (EOD), once a morning (OM)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard antihypertensive pharmacotherapy
Number of subjects: 88
Study: 23807278

Group type: EXPERIMENTAL
Intervention: 12 ml of 0.5 % bupivacaine plus 150 mg magnesium sulphate (in 3 ml 0.9 % saline)
Number of subjects: 50
Study: 23248063

Group type: EXPERIMENTAL
Intervention: Immediate renal denervation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Crossover to renal denervation after 6 months
Number of subjects: 47
Study: 20211816

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 0
Study: 18332043

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 5187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5187
Study: 15707414

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cyclosporine (CyA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Monitoring and preemptive withdrawal of immunosuppression
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reduction of immunosuppression
Number of subjects: 200
Study: 11861346

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) use in patients with severe ventricular impairment and unstable angina
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PAC use in patients with ventricular impairment alone
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PAC use in patients with unstable angina alone
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PAC use in routine patients without complicating risk factors
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PAC use frequency and practice volume
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Continuing medical education participation
Number of subjects: 345
Study: 10414567

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Repeat radiofrequency neurotomy
Number of subjects: 28
Study: 7677296

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 246

Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 246
Study: 2123183

Group type: EXPERIMENTAL
Intervention: Insulin + glibenclamide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Insulin + placebo
Number of subjects: 26
Study: 6972513

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (12.5 mg/kg, two doses on the first day of life)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30802635

Group type: EXPERIMENTAL
Intervention: Fan + exercise advice
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calming Hand + exercise advice
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fan + Calming Hand + exercise advice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exercise advice alone
Number of subjects: 40
Study: 29093180

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (IV or SC) at doses of 1, 4, or 7 mg/kg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (IV)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (highest-dose IV group)
Number of subjects: 49
Study: 25870986

Group type: EXPERIMENTAL
Intervention: ART12 (12 weeks of antiretroviral therapy)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ART48 (48 weeks of antiretroviral therapy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care (no ART)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Stopping ART
Number of subjects: 200
Study: 23823106

Group type: EXPERIMENTAL
Intervention: PEEP 0 cm H2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP 6 cm H2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP 12 cm H2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP (various levels)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP and positioning
Number of subjects: 30
Study: 21793420

Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze eurhythmics
Number of subjects: 0
Study: 20086319

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Skimmed curd protein (SMP)
Number of subjects: 28
Study: 17275199

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 218

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Smoking status and pack years
Number of subjects: 218
Study: 15012784

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No pancreatic enzyme replacement therapy (no PERT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 6
Study: 11675363

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) treatment
Number of subjects: 0
Study: 9601155

Group type: EXPERIMENTAL
Intervention: Proctoclysis (rectal hydration) with normal saline or tap water at a rate of 250 +/- 63 cc/hr for 15 +/- 8 days
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Proctoclysis
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hypodermoclysis
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 78
Study: 7527181

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Coronary arteriography (CAG)
Number of subjects: 14
Study: 3198778

Group type: EXPERIMENTAL
Intervention: Interviews with a psychologist
Number of subjects: 26

Group type: COMPARATOR
Intervention: No interviews (control group)
Number of subjects: 26
Study: 30835085

Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30702488

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg) plus Lansoprazole (30 mg daily)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo plus Lansoprazole (30 mg daily)
Number of subjects: 300
Study: 28820909

Group type: EXPERIMENTAL
Intervention: Structured moderate intensity walking, resistance, and flexibility physical activity program
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 1635
Study: 25525195

Group type: EXPERIMENTAL
Intervention: 600 mg of darunavir (DRV600) once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: 800 mg of darunavir (DRV800) once daily
Number of subjects: 100
Study: 23081681

Group type: EXPERIMENTAL
Intervention: CYP2C9*2 or *3 variant allele
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: CYP2C9*3 allele
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Cigarette smoking among wild-type individuals
Number of subjects: 928
Study: 21729811

Group type: COMPARATOR
Intervention: Lidocaine 0.5 mg/kg (Group L)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Lidocaine 0.5 mg/kg‐ephedrine 30 μg/kg (Group LE)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ephedrine 30 μg/kg (Group E30)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ephedrine 70 μg/kg (Group E70)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ephedrine groups (E30 and E70)
Number of subjects: 165
Study: 19902675

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg) intrauterine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 17121171

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg for 4 weeks followed by sertraline 50 mg to 100 mg for 2 weeks for nonresponders
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 48
Study: 15371138

Group type: EXPERIMENTAL
Intervention: Interferon-based therapies
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing support and intervention
Number of subjects: 29
Study: 11401011

Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 9678817

Group type: COMPARATOR
Intervention: Purified immunoglobulins from hyperimmune bovine colostrum for 1 month
Number of subjects: 24
Study: 8053576

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 27
Study: 3133529

Group type: EXPERIMENTAL
Intervention: Propicillin (3 mega units transorally for 12 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29946650

Group type: EXPERIMENTAL
Intervention: Hybrid-coat combined with composite resin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Composite resin directly
Number of subjects: 70
Study: 28594761

Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 163

Group type: COMPARATOR
Intervention: Suture
Number of subjects: 163
Study: 26576673

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture plus lifestyle modification
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 150
Study: 23151089

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 100
Study: 22014336

Group type: EXPERIMENTAL
Intervention: Site-specific hysteroscopic biopsy-induced injury on the posterior endometrium during the D4-D7 period of the controlled ovarian hyperstimulation cycle
Number of subjects: 30

Group type: COMPARATOR
Intervention: No hysteroscopic biopsy-induced endometrium injury
Number of subjects: 30
Study: 18433043

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 58
Study: 12663273

Group type: EXPERIMENTAL
Intervention: 1.7 g EPA+DHA/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 9.5 g ALA/d
Number of subjects: 150

Group type: COMPARATOR
Intervention: n-6 PUFA control
Number of subjects: 150
Study: 10217581

Group type: EXPERIMENTAL
Intervention: 1.2 mg of alum-precipitated mAb 13B8.2
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 7618705

Group type: EXPERIMENTAL
Intervention: Esmolol (300 micrograms.kg‐1.min‐1 during CPB after bolus of 2 mg/kg prior to CPB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2144203

Group type: EXPERIMENTAL
Intervention: Zoladex and flutamide
Number of subjects: 149

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 149
Study: 345733

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30142288

Group type: EXPERIMENTAL
Intervention: Participants receiving financial gratification in advance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants not receiving financial gratification in advance
Number of subjects: 0
Study: 27166171

Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS (1A‐tDCS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS (1C‐tDCS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS (2C‐tDCS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 25884605

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 23648347

Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-ASCT
Number of subjects: 27
Study: 21210796

Group type: EXPERIMENTAL
Intervention: MassHealth hospital pay-for-performance program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control hospitals (propensity-score matched)
Number of subjects: 62
Study: 18549515

Group type: EXPERIMENTAL
Intervention: Active rehabilitation (group R) - 10 sessions including exercises on a stabilometric platform, point de mire, and a series of five exercises repeated five times daily.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active rehabilitation (group R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group C) - told to 'perform their daily activities'.
Number of subjects: 40
Study: 17596639

Group type: EXPERIMENTAL
Intervention: Caregiver skill building intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Information and support oriented comparison condition
Number of subjects: 143
Study: 14756468

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg and pseudoephedrine 120 mg twice daily for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg and montelukast 10 mg once daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 0
Study: 11294481

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg for nortriptyline comparator trial; 50-100 mg for fluoxetine comparator trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study: 9021962

Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3 10 million units (MU) three times a week for 24 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3 lower doses (1.0, 2.5, 5.0 MU)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3
Number of subjects: 77
Study: 7997708

Group type: COMPARATOR
Intervention: Standard methods for survival analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refined estimate of survival using auxiliary information
Number of subjects: 0
Study: 29370144

Group type: EXPERIMENTAL
Intervention: Whey Proteins (WP) pre-meal (20 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water (control) pre-meal
Number of subjects: 24
Study: 27784290

Group type: EXPERIMENTAL
Intervention: Enhanced Care (nutrition, physical activity, and mental health)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Standard Care (nutrition and physical activity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active Control (non-nutrition, physical activity, or mental health)
Number of subjects: 12
Study: 25514542

Group type: EXPERIMENTAL
Intervention: MPH-MLR 80 mg capsule or sprinkles
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ritalin IR 25 mg
Number of subjects: 26
Study: 21975593

Group type: EXPERIMENTAL
Intervention: Dissonance-based eating disorder prevention program
Number of subjects: 481

Group type: COMPARATOR
Intervention: Healthy weight control program
Number of subjects: 481

Group type: COMPARATOR
Intervention: Expressive writing control condition
Number of subjects: 481

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 481
Study: 20132154

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19468079

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16510657

Group type: EXPERIMENTAL
Intervention: INT (n = 377)
Number of subjects: 985

Group type: COMPARATOR
Intervention: FUO (n = 608)
Number of subjects: 985
Study: 15570920

Group type: EXPERIMENTAL
Intervention: TS-1 + cisplatin (CDDP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cisplatin (CDDP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: TS-1 alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: CPT-11 with CDDP therapy
Number of subjects: 19
Study: 10772604

Group type: EXPERIMENTAL
Intervention: 50 mg/day naltrexone
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Naltrexone with intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Naltrexone without intervention
Number of subjects: 196
Study: 9310275

Group type: EXPERIMENTAL
Intervention: Bisoprolol once daily for 8 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nifedipine retard twice daily for 8 weeks
Number of subjects: 82
Study: 8325059

Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 14

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 14
Study: 3488184

Group type: EXPERIMENTAL
Intervention: Nd-YAG laser photocoagulation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonrandomized group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 33
Study: 29492652

Group type: EXPERIMENTAL
Intervention: Cortico-spinal excitability measures (resting motor thresholds and motor evoked potentials)
Number of subjects: 18